Lexicon Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (LXRX)

Q2 2012 Earnings Call

July 31, 2012, 11:00 a.m. ET

Executives

Alex Abuin – VP Communications and Alliance Management

Dr. Arthur Sands – President and CEO

Brian Zambrowicz, EVP, Chief Scientific Officer

Jeff Wade – EVP, Corporate Development and Chief Financial Officer

Analysts

Matt Lowe – JPMorgan

Liana Moussatos – Wedbush Securities

Alan Carr – Needham & Company

David Friedman – Morgan Stanley

Nicholas Bishop – Cowen and Company

Stephen Willey – Stifel Nicolaus

Presentation

Operator

Thank you for holding. Welcome to the Lexicon Pharmaceuticals' Second Quarter 2012 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Lexicon’s request.

At this time, I would like to introduce your host for today’s call, Alex Abuin, Vice President Communications and Alliance Management. Please go ahead Doctor Abuin.

Alex Abuin

Good morning and welcome to the Lexicon Pharmaceuticals' second quarter 2012 conference call. I am Alex Abuin, and with me today are Dr. Arthur Sands, Lexicon’s President and Chief Executive Officer; Dr. Brian Zambrowicz, Lexicon’s Executive Vice President and Chief Scientific Officer; Dr. Jeff Wade, Lexicon’s Senior Vice President of Clinical Development and Chief Medical Officer.

We expect that you have seen a copy of our earnings press release that was distributed this morning. During this call, we will review the information provided in the release, provide an update on our clinical programs, and then use the remainder of our time to answer your questions.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

4 Smaller Biotech Names Worth Researching

7 Things to Watch in Biotech Now

These 3 Biotech Stocks Are Already Moving Wildly on Thursday